Therma Bright Stock: A High-Growth Opportunity in Medical Device Technologies, boosting Therma Bright’s stock price by approximately 500%
| Ticker: | THRM.V (TSX.V) | |
| Current Price: | $0.05 | |
| 52-Week Range: | $0.01 - $0.10 | |
| Market Cap: | $21 Million | |
| Shares Outstanding: | 420,615,855 |
Overview
Canadian-listed Therma Bright (THRM.V) has captured investor attention with a remarkable 200% surge following a positive notification from the U.S. Department of Health and Human Services' Centers for Medicare & Medicaid Services (CMS). This notification pertains to their innovative Venowave VW5 device, a medical compression pump designed to enhance blood circulation in the lower extremities.
Company Profile
Therma Bright is a small-cap growth stock listed on the TSX Venture Exchange (TSXV). The company specializes in proprietary diagnostic and medical device technologies, focusing on innovative solutions to enhance patient care and outcomes. Therma Bright, is a developer and partner in a range of leading edge, proprietary diagnostic and medical device technologies focused on providing consumers and medical professionals with quality, innovative solutions that address some of today's most important medical and healthcare challenges. Therma Bright is developing, acquiring, manufacturing and marketing proprietary healthcare and medical devices for the consumer and institutional marketplace focused on 3 key strategic areas: Respiratory Disease, Vascular Health and Consumer Medical Devices.
Key Developments
On August 1, 2024, Therma Bright issued a press release announcing the anticipated approval of permanent Current Procedural Terminology (CPT) and HealthCare Common Procedure Coding System (HCPCS) codes for the Venowave VW5 device. This approval is expected to significantly boost the company’s market penetration and revenue potential.
Product Highlight: Venowave VW5
The Venowave VW5 is an FDA-approved circulation booster that addresses issues of poor circulation in the lower extremities. The technology was developed by engineer John Saringer and co-developed by world-renowned clinical researcher and hematologist, Dr. Jack Hirsch. Their patented Venowave technology ensures that wearers will never have to worry about immobility again. The comfort and ease of use result in higher patient compliance and better overall results.
Core Venowave Features from Research & Development Efforts
- Mobile: Weighing less than 0.5 pounds each, the Venowave fits snugly to the back of each calf. No cords, no compression tanks – just two “AA” batteries needed for operation. This revolutionary technology permits participation in normal lifestyle activities that were once impossible with bulky, noisy, and immobile devices.
- Simple-to-use: From the hospital to the home, Venowave technology is an easy and simple treatment device to adopt for Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) patients of all ages and health conditions. The device’s large neoprene straps are adjustable and breathable – providing comfort for legs and calves of all sizes. Regardless of your leg position, the product automatically adjusts its massage-like therapy to keep your blood circulation flowing normally.
- Life-saving: The life-threatening effects of DVT, Chronic Venous Insufficiency (CVI), and Post-Thrombotic Syndrome (PTS) are greatly reduced with the use of the Venowave. Its venous-return assisting capabilities are designed to: (i) Treat primary thrombosis, (ii) Enhance circulation, and (iii) Decrease post-operative limb pain and swelling. Clinical research conducted on patients suffering from PTS concluded that the Venowave technology increased venous blood flow by 64% after 2 minutes of use and by 88% after 50 minutes of use. Researchers further concluded that compared with standard PTS therapies, approximately one-third of severe PTS patients reported clinical improvement.
Market Potential
Therma Bright's Venowave VW5 holds significant potential in the medical device market. The product's unique features cater to a growing demographic of patients with circulation issues. As the company secures CPT and HCPCS codes, it positions itself for substantial revenue growth, making it an attractive investment for both retail and institutional investors.
Additional Portfolio
In addition to the Venowave VW5, Therma Bright has a portfolio that includes a Digital Cough technology and investments in an Inhaled Statin Drug Technology and Ischemic Stroke Clot Retriever technology. In addition, Therma Bright has a portfolio of pain relief and skincare technologies/applications, COVID-19 diagnostics, and a marketplace with novel marketing techniques. This diversified portfolio provides additional growth avenues and revenue streams.
Investment Case
Therma Bright's stock experienced a significant sell-off, dropping to $0.01 per share. However, with the recent developments, investors are recognizing the revenue potential of the Venowave VW5, alongside the company's portfolio of other medical devices. The stock's recent performance indicates renewed investor confidence and highlights the opportunity for substantial upside.
Conclusion
ArcStone Financial Pulse is excited to share this promising investment opportunity. Therma Bright's innovative Venowave VW5 device and its upcoming approval for CPT and HCPCS codes position the company for significant growth. Investors should closely monitor this stock as it continues to develop its product portfolio and expand market reach.
Disclaimer
This report is not a recommendation to buy or sell Therma Bright stock. The views expressed are those of ArcStone Financial Pulse. Certain principals at ArcStone Securities & Investments are personal shareholders of Therma Bright.
Update: August 13, 2024 - Therma Bright’s stock price has increased by approximately 500%.
About ArcStone Securities and Investments Corp.
ArcStone Securities and Investments Corp. is a leading financial services firm specializing in capital markets, corporate finance, and strategic advisory services. We assist clients in raising growth capital, navigating IPOs and RTOs, and executing mergers and acquisitions with precision and expertise. Additionally, we provide comprehensive debt financing solutions and a wide range of financial services to meet the unique needs of our clients. Our dedicated team of professionals offers tailored solutions to help businesses achieve their financial objectives and thrive in a competitive market. Discover how ArcStone can support your growth journey by visiting our website at arcstoneglobalsecurities.com.
ArcStone Financial Pulse Team
Stay informed with the latest market trends and investment insights from ArcStone Securities and Investments Corp. Subscribe to our newsletter for more detailed reports and analysis.
